Crossmark

Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

Crossref DOI link: https://doi.org/10.1007/s13311-021-01148-w

Published Print: 2021-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Hartung, Hans-Peter

Mares, Jan

Meuth, Sven G.

Berger, Thomas
License Information

Text and Data Mining valid from 2021-07-01

Text and Data Mining valid from 2021-07-01

Version of Record valid from 2023-08-18
More Information

This article is maintained by: Elsevier

Article Title: Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

Journal Title: Neurotherapeutics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s13311-021-01148-w

CrossRef DOI link to the associated document: https://doi.org/10.1007/s13311-021-01102-w

Content Type: simple-article

Copyright: Copyright © 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.

Document is current

Any future updates will be listed below